Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 880 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia May 23, 2022 GreaterGood Charities Provides Supplies and Support to People and Pets After... December 17, 2021 Disguising Cancer as an Infection Helps the Immune System Eliminate Tumors July 22, 2022 FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer January 7, 2026 Load more HOT NEWS ESMO Award for Immuno-Oncology 2025 Recipient Announced EMA Recommends Extension of Indications for Darolutamide Zanubrutinib’s Approval Improves Targeted Treatment for CLL Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib...
